PharmAthene (PIP) Slammed on SparVax rPA Clinial Hold News
Tweet Send to a Friend
Up)
PharmAthene (AMEX: PIP) shares are getting hit early Friday following news its SparVax rPA was place on clinical hold by the FDA.
Shares are down over 20 percent in early trading.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Shares are down over 20 percent in early trading.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Will Erickson Air-Crane (EAC) Stock Crash and Burn?
- Elliott Management said to take significant stake in NetApp (NTAP) - Bloomberg
- Erickson Air-Crane (NYSE: EAC) 'The Real Deal' - Cramer
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader Talk
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
